In today’s briefing:
- Indegene IPO – Marquee Clients, Strong Track Record, Decent Valuation
- Bumrungrad Hospital (BH TB): Record High Margins in 1Q24; Reasonable Growth in Foreign Patients
- LEXX: Begin with the End in Mind
- MDXG: MACs Give Credit for Efficacy
- ONVO: Positive Phase 2 Results Bolsters Outlook
- Align Technology: Will The Orthodontic Market Improvements Last? – Major Drivers
- TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025
- Biogen Inc.: Advancement of Neuroscience Drug Delivery & 6 Major Drivers
- BioMarin Pharmaceutical Inc.: What Is Their Expected Revenue Growth After Ther Efforts Towards Streamlining Expenditure? – Major Drivers
- Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! – Major Drivers
Indegene IPO – Marquee Clients, Strong Track Record, Decent Valuation
- Indegene Limited (1864095D IN) is looking to raise US$220m in its India IPO, via selling a mix of primary and secondary shares.
- Indegene is a “digital-first” commercialisation firm with an exclusive focus on the global life sciences industry.
- In this note, we will look at peers and discuss our thoughts on valuation.
Bumrungrad Hospital (BH TB): Record High Margins in 1Q24; Reasonable Growth in Foreign Patients
- Bumrungrad Hospital Pub Co (BH TB) reported strong 1Q24 results, with revenue growing 8% YoY to THB6,576M, EBITDA climbing 22% to THB2,676M, and net profit increasing 25% to THB1,985M.
- International patients revenue increased 6% YoY. Slow growth in the revenue from international patients can be attributable to high base, as it grew by a whopping 105% YoY in 1Q23.
- With tight control on cost, the company has reported record high margins in 1Q24, with gross, EBITDA, and net margin reaching 51.7%, 40.7%, and 30.2%, respectively.
LEXX: Begin with the End in Mind
- Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.
- It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.
- DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.
MDXG: MACs Give Credit for Efficacy
- MiMedx is a wound care and therapeutic biologics company, developing and distributing allografts.
- The company derives its products from human placental tissues processed using the Purion technology.
- MiMedx differentiates itself in the regenerative medicine market through the substantial library of supportive research for its products.
ONVO: Positive Phase 2 Results Bolsters Outlook
- Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process.
- The company recently released positive Phase 2 results for one of its primary treatments-FXR314.
- These results are very encouraging and bolsters our belief in the future prospects for ONVO.
Align Technology: Will The Orthodontic Market Improvements Last? – Major Drivers
- Align Technology Inc. started the year 2024 on a strong note with better than expected revenue and earnings for the first quarter.
- The company reported a 5.8% year-over-year rise in worldwide revenues, driven by a 3.5% growth from the Clear Aligner segment and a whopping 17.5% growth from Systems and Services.
- The Align First Quarter 2024 Earnings call highlighted revenue growth across all regions, powered by robust volume growth of Clear Aligners, especially in the Asia Pacific region.
TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025
- On April 1, 2024, Tonix Pharmaceuticals Holding Corp.
- (TNXP) announced financial results for the fourth quarter and full year 2023 and provided a business update.
- Tonix will be filing a New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.
Biogen Inc.: Advancement of Neuroscience Drug Delivery & 6 Major Drivers
- Biogen’s first quarter 2024 earnings reflect the company’s commitment to growth and innovation within its portfolio, coupled with an unwavering focus on improving profitability.
- The company has seen growth in its earnings per share for the first time in several years, largely due to the performance of its underlying business.
- CEO, Chris Viehbacher, praised the company’s teams for their commitment and the role they play in driving the company’s success, notwithstanding the ongoing changes within the company.
BioMarin Pharmaceutical Inc.: What Is Their Expected Revenue Growth After Ther Efforts Towards Streamlining Expenditure? – Major Drivers
- BioMarin Pharmaceutical Inc. reported strong financial results for Q1 2024, while implementing significant advances as part of the company’s new corporate vision and strategy.
- According to the firm, this is done in the interest of positively influencing patients’ lives and generating value for shareholders, with several strategic initiatives currently underway.
- Based on the company’s R&D portfolio assessment, three assets were chosen to be accelerated based on their potential to transform patients and shareholder value.
Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! – Major Drivers
- Chemed Corporation’s management recently their financial results for the first quarter of 2024, which ended on March 31, 2024.
- The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter.
- VITAS, Chemed’s healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
